Dicerna Pharmaceuticals announced that it has appointed David Madden as its chairman.
The company's previous chairman, Oxford Biosciences Partners partner Douglas Fambrough, remains on Dicerna's board.
Most recently, Madden was interim CEO of public pharmaceutical firm Adolor. Before that, he was co-CEO of Royalty Pharma. He holds a BS in electrical engineering from Union College and an MBA from Columbia University.